These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2775663)

  • 1. Antibodies to glycosaminoglycans and cardiolipin in patients with chronic myeloid leukaemia.
    Cheng HM; Sam CK
    Br J Haematol; 1989 Aug; 72(4):594. PubMed ID: 2775663
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma levels of highly sulphated glycosaminoglycans are raised in patients with chronic myeloid leukaemia.
    Craig JI; Reilly KM; Yap PL; Dawes J; Allen L; Parker AC
    Br J Haematol; 1988 Sep; 70(1):27-9. PubMed ID: 3179226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of cross-reactivity between anticardiolipin antibodies and glycosaminoglycans.
    Galli M; Cortelazzo S; Barbui T
    Thromb Res; 1990 Jul; 59(2):363-7. PubMed ID: 2237814
    [No Abstract]   [Full Text] [Related]  

  • 4. BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia.
    Clark RE; Christmas SE
    Leuk Lymphoma; 2001; 42(5):871-80. PubMed ID: 11697642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell recognition of bcr/abl in healthy donors and in patients with chronic myeloid leukaemia.
    Westermann J; Schlimper C; Richter G; Mohm J; Dörken B; Pezzutto A
    Br J Haematol; 2004 Apr; 125(2):213-6. PubMed ID: 15059144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies to lymphoblastoid interferon.
    Galton JE; Bedford P; Scott JE; Brand CM; Nethersell AB
    Lancet; 1989 Sep; 2(8662):572-3. PubMed ID: 2570278
    [No Abstract]   [Full Text] [Related]  

  • 7. Is there immune surveillance against chronic myeloid leukaemia? Possibly, but not much.
    Gale RP; Opelz G
    Leuk Res; 2017 Jun; 57():109-111. PubMed ID: 28359029
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecular status of individual CFU-GM colonies derived from chemotherapy-mobilised peripheral blood stem cells in chronic myeloid leukaemia.
    Broughton CM; Sherrington P; Pender NT; Clark RE
    Genes Chromosomes Cancer; 1997 Apr; 18(4):292-8. PubMed ID: 9087569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variant (3;21) translocation and megakaryocytic involvement in blastic crisis of Philadelphia positive chronic myeloid leukaemia.
    Aventin A; Mecucci C; Van Orshoven A; Delannoy A; Van den Berghe H
    Br J Haematol; 1989 Apr; 71(4):562-4. PubMed ID: 2713276
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-interferon antibodies in alpha interferon treated patients with chronic myeloid leukaemia.
    Aitchison R; Allen P; Schey S; Newland AC
    Br J Haematol; 1991 Jul; 78(3):465-7. PubMed ID: 1873235
    [No Abstract]   [Full Text] [Related]  

  • 11. Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Román J; Serrano J; Jiménez A; Castillejo JA; Reina ML; González MG; Rodríguez MC; García I; Sánchez J; Maldonado J; Torres A
    Haematologica; 2000 Feb; 85(2):173-80. PubMed ID: 10681725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune responses to chronic myeloid leukaemia.
    Barrett A; Jiang YZ
    Bone Marrow Transplant; 1992 May; 9(5):305-11. PubMed ID: 1617313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Rho-ROCK pathway as a new pathological mechanism of innate immune subversion in chronic myeloid leukaemia.
    Basbous S; Levescot A; Piccirilli N; Brizard F; Guilhot F; Roy L; Bourmeyster N; Gombert JM; Herbelin A
    J Pathol; 2016 Nov; 240(3):262-268. PubMed ID: 27513300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GATA1 mutational analysis in chronic myeloid leukaemia.
    Halsey C; Fisher C; Strathdee G; Gibson B; Holyoake T; Vyas P; Graham G
    Br J Haematol; 2007 May; 137(4):375-6. PubMed ID: 17408401
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeting primary human leukaemia cells with RNA interference: Bcr-Abl targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells.
    Withey JM; Marley SB; Kaeda J; Harvey AJ; Crompton MR; Gordon MY
    Br J Haematol; 2005 May; 129(3):377-80. PubMed ID: 15842662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific point mutations that activate v-abl are not found in Philadelphia-negative chronic myeloid leukaemia, Philadelphia-negative acute lymphoblastic leukaemia or blast transformation of chronic myeloid leukaemia.
    Melo JV; Goldman JM
    Leukemia; 1992 Aug; 6(8):786-90. PubMed ID: 1353550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percentage of CD34 cells in a minimum 500-cell count in bone marrow trephines of patients with chronic myeloid leukaemia provides the best correlation with aspirate blast count.
    Elliot V; Marin D; Horncastle D; Elderfield K; Apperley JF; Lampert IA; Naresh K
    Br J Haematol; 2005 Aug; 130(3):460-1. PubMed ID: 16042700
    [No Abstract]   [Full Text] [Related]  

  • 18. Chronic myeloid leukaemia. I. Some observations on chronic myeloid leukaemia.
    GALTON DA
    Br J Radiol; 1953 Jun; 26(306):285-90. PubMed ID: 13051542
    [No Abstract]   [Full Text] [Related]  

  • 19. Neutrophil functions in chronic myeloid leukemia.
    Carulli G; Azzarà A; Papineschi F; Rizzuti A; Grassi B; Ambrogi F
    Leuk Res; 1990; 14(9):823-4. PubMed ID: 2232855
    [No Abstract]   [Full Text] [Related]  

  • 20. Antibody recognition of the tumor-specific bcr-abl joining region in chronic myeloid leukemia.
    van Denderen J; Hermans A; Meeuwsen T; Troelstra C; Zegers N; Boersma W; Grosveld G; van Ewijk W
    J Exp Med; 1989 Jan; 169(1):87-98. PubMed ID: 2462613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.